Pulse Biosciences Welcomes New Executive Team Members

Pulse Biosciences Inc. has appointed David Kenigsberg, M.D., as chief medical officer of Electrophysiology and named Andrea Natale, M.D., as a medical advisor. Natale joins existing advisors Vivek Reddy, M.D., and Jacob Koruth, M.D.; together they will support the development and clinical efforts for the Pulse Biosciences nano-PFA 360 Cardiac Catheter.

“We are strengthening our team with the addition of these renowned physicians who will contribute to generating high quality clinical data that demonstrates the clinical performance profile of the 360 catheter,” Pulse Biosciences President/CEO Burke T. Barrett said. “I want to thank Drs. Reddy and Koruth for their contributions in the pre-clinical and clinical evaluations of the 360 catheter to date.”

Dr. Kenigsberg is a practicing cardiac electrophysiologist with a passion for treating atrial fibrillation over his career. He is the founder of Florida Heart Rhythm Specialists and Ft. Lauderdale Heart & Rhythm Surgical Center. He has been the medical director of the Electrophysiology Lab at HCA Westside Medical Center in Plantation, Fla., since 2007 and has published numerous scholarly articles in peer-reviewed medical journals. He has advised in the development of and has been the primary investigator/co-investigator in numerous clinical trials involving ablation tools. Dr. Kenigsberg is a fellow of the American College of Cardiology and the Heart Rhythm Society. He is president of the Florida Chapter of the American College of Cardiology and is a member of the American College of Cardiology Board of Governors.

“I am inspired by the potential of nano-PFA and the unique catheter design of the 360 catheter that is already demonstrating the ability to isolate pulmonary veins with ease and speed,” Dr. Kenigsberg said. “I was impressed when I saw the 360 catheter in use and am excited to work with Pulse to deliver clinical data with the 360, which I believe will substantially advance the treatment of atrial fibrillation. I look forward to supporting this team through its next phase of clinical development.”

Dr. Natale is executive medical director of the Texas Cardiac Arrhythmia Institute at St. David’s Medical Center in Austin, Texas, and the National Medical Director of Cardiac Electrophysiology for HCA Healthcare. A dedicated researcher and pioneer, Dr. Natale focuses on innovative advances in atrial fibrillation treatment. He has been and continues to be involved in many first-in-human trials to test investigational devices, recently performing the first pre-clinical and clinical studies to develop and perfect ablation catheters using a novel ablation energy source known as irreversible electroporation.

“This is an exciting time in electrophysiology as pulsed field ablation technologies are becoming widely adopted and advancing the standard of care. I am excited to support the Pulse team in the clinical efforts for the 360 catheter,” Dr. Natale stated.

Pulse Biosciences is a bioelectric medicine company committed to health innovation that potentially can improve patients’ quality of life. Its proprietary CellFX nsPFA technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The company is actively pursuing the development of its CellFX nsPFA technology for use in treating atrial fibrillation and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers. Pulse Biosciences is headquartered in Miami, Fla., and maintains an office in Hayward, Calif.